Evgen Pharma Share Discussion Threads

[pdt] 01/9/2017 13:41

NICE turns down AZ's Faslodex



It will be interesting if results from the Evgen trial show that SFX-01 will routinely extend progression free survival beyond six months. We know that applies to at least one participant following the compassionate use programme announcement.

Here is a quote from the above article which puts the value of such extensions in context;

"According to the data from the Phase III FALCON trial, median progression-free survival (PFS) was significantly longer with Faslodex than with anastrozole, at 16.6 months versus 13.8 months"

So potentially adding 6+ months to the above numbers. Still early days but certainly very encouraging.

[pdt] 16/8/2017 20:35

More research just published by the University of Maryland school of medicine;

"Combination Cisplatin and Sulforaphane Treatment Reduces Proliferation, Invasion and Tumor Formation in Epidermal Squamous Cell Carcinoma"

Extract From the conclusion;

"Both agents suppress tumor formation, but enhanced suppression is observed with combined treatment. Moreover, both agents reduce the number of tumor-resident cancer stem cells. SFN treatment of cultured cells or tumors increases apoptosis and p21Cip1 level, and both agents increase tumor apoptosis. We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma."



This must be encouraging for Evgen's Metastatic Breast Cancer study.

[pdt] 02/8/2017 15:56

New published research on SFX-01 and Osteoarthritis

"In conclusion, we report that SFX-01® improves bone microarchitecture in vivo, produces corresponding changes in bone cell behaviour in vitro to enhance indices of bone mechanical strength and produces greater symmetry in gait, without marked effects on cartilage lesion severity in STR/Ort osteoarthritic mice. Our findings support both osteotrophic roles and novel beneficial gait effects for SFX-01® that appear to be independent of articular cartilage lesion development in this model of spontaneous OA."



I see that the work was partly funded by Arthritis Research UK

And a quick search revealed that OA affects over 100m people in the US alone. The treatments all seem to be palliative and do not treat the problem.

[pdt] 01/8/2017 20:45

I see the RVC has put out a press release in respect of getting grant funding for a 4 year PhD study into osteoarthritis using SFX-01



Four years seems like a long time but hopefully there will be periodic updates.

[pdt] 29/7/2017 17:23

timbo and paxman

Thanks for posting links and comments, all very interesting and positive.

I can see lots of people knocking on the Evgen door wanting to run collaborative trials over the coming months in all sorts of indications. They are a small team so hopefully it doesn't distract them from their key focus.

[paxman] 29/7/2017 14:03

My guess is of today Evgen have things covered pretty tight on a pharma grade compound which would meet FDA dosage rules consistently.

e.g. here's a 2015 Slideshare from a member of the US's NIH addressing DMD:



Check out the last 2 pages - 'Next Steps' - collaborate with Evgen.

Don't remember Evgen mentioning DMD.

[timbo003] 29/7/2017 11:56

>>>>PDT

Yes, that seems to confirm that other related compounds are likely to have similar activity which helps validate Evgen's decision to license a series of homologous compounds from The University of Seville back in November 2015 (in exchange for a small royalty ≤ 1%):



Whilst looking for the John Hopkins University ASD application (see previous post), I came across what I suspect is the patent application concerning the Saville University compounds now licensed to Evgen:

[paxman] 28/7/2017 16:44

Not convinced they'd have to talk to John Hopkins. Surely John Hopkins could only patent their method of storing or freezing or delivering or measuring sulforaphane, a naturally occurring molecule.

SFX-01 won't need similar storage etc.

Any attempt to patent human body processes would fail. Besides there's too much prior art ( research) in sulforaphane. IMHO only synthetic chemical compositions, e.g. SFX-01, are likely to be granted. I see a JH patent application in 2012 but not granted to date.
Evgen are quite rightly screening loads of analogues and no doubt patenting the most promising.

[paxman] 28/7/2017 10:12

Thanks timbo003 - your graphs are easier to interpret than the black and white ones on page 32 of the AGM presentation.

[paxman] 28/7/2017 10:07

What I like is the minimal placebo effect, so any SFX-01 effect in a phase 2 should hopefully be easy to segregate. Also the reversion to pre treatment status when sulforaphane is no longer taken suggests genuine efficacy.

Interesting results. I think current drugs used for autism are symptom reducers. Taking autism prevalence off the internet - about 1% of the global population - 70 million - and taking a quick look at the above data - 50% of users have a more than 20% reduction in symptoms - suggests a very large market.

Hope Evgen raise some more money and accelerate all these phase 2 indications trials.

[timbo003] 27/7/2017 16:10

Today's (unexpected) performance just has to be worth an animated gif!

[timbo003] 27/7/2017 11:37

Indeed PDT

The slides in the appendices describing the third party studies are particularly interesting, I did not realise for example, that there are six ongoing clinical studies detailed on Clintrials.gov looking at autism.

As general awareness of the Evgen stabilisation technology becomes more widespread within the academic clinical research community, along with the realization that Evegen has a unique ability to supply clinical grade, stable, Sulforaphane for clinical trials purposes, means that Steve Franklin will probably be spending more and more time dealing with the queue of academics who want to collaborate with Evgen on clinical programs.

[pdt] 27/7/2017 10:47

Timbo - thanks for posting the new presentation.

It is mostly the same as the presentation at the end of June however new additions are potential third party studies by Universities of Madrid and Dundee in Parkinson's and Non-alcoholic Fatty Liver disease.

It is great that Evgen retains commercialization rights in these studies and just has to provide SFX. So we have had Triple Negative Breast Cancer announced a few days ago and Osteoarthritis with Royal Veterinary College announced yesterday. And Autism, Parkinson's and NAFL to follow soon.

[timbo003] 27/7/2017 09:57

Here's the slide on the current pipeline (now added to the header)

Note the investigator initiated studies (Autism and regenerative medicine), these should be a free carry for the company (except for the supply of the AS):

[timbo003] 27/7/2017 09:50

The AGM presentation now available on the web site:

[timbo003] 26/7/2017 21:19

No sign of the AGM presentation slides yet on the Evgen web site, if they don't appear tomorrow I will chase up.

[peterm10] 26/7/2017 19:08

Not a big poster but a good RNS today on Manchester cancer centre doing trials on breast cancer patients. Touches everyone and gotta hope this less invasive treatment is going to work. If it does I can also treat the missus to a top holiday or two

[pdt] 14/7/2017 17:22

Here is a great article summarising the research into the benefits of Sulforaphane with links to the scientific studies for each claim. A very neat summary, worth a look.